SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: GlobeNewswire
MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO’s management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division chief of the Pediatric Endocrinology Division at the University of Florida and Silverstein Family Eminent Scholar Chair in Pediatric Endocrinology. Webinar Details and Registration Information Date: Tuesday, January 28, 2025 Time: 8:00 am ET Register for the event here or join the conference call through the Events section of the SAB BIO Company we
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.MarketBeat
- SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.MarketBeat
- First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1DGlobeNewswire
- SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D [Yahoo! Finance]Yahoo! Finance
- SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1DGlobeNewswire
SABS
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- SABS's page on the SEC website